Saxena | Coronavirus Disease 2019 (COVID-19) | Buch | sack.de

Saxena Coronavirus Disease 2019 (COVID-19)



Epidemiology, Pathogenesis, Diagnosis, and Therapeutics

1. Auflage 2020, 213 Seiten, Kartoniert, Paperback, Format (B × H): 157 mm x 235 mm, Gewicht: 367 g Reihe: Medical Virology: From Pathogenesis to Disease Control
ISBN: 978-981-1548-16-1
Verlag: Springer, Berlin


Saxena Coronavirus Disease 2019 (COVID-19)

This book provides a comprehensive overview of recent novel coronavirus (SARS-CoV-2) infection, their biology and associated challenges for their treatment and prevention of novel Coronavirus Disease 2019 (COVID-19). Discussing various aspects of COVID-19 infection, including global epidemiology, genome organization, immunopathogenesis, transmission cycle, diagnosis, treatment, prevention, and control strategies, it highlights host-pathogen interactions, host immune response, and pathogen immune invasion strategies toward developing an immune intervention or preventive vaccine for COVID-19.

An understanding of the topics covered in the book is imperative in the context of designing strategies to protect the human race from further losses and harm due to SARS-CoV-2 infection causing COVID-19.

Zielgruppe


Research


Autoren/Hrsg.


Weitere Infos & Material


Chapter 1_Global trends in epidemiology of Coronavirus Disease 2019 (COVID-19). -Chapter 1.1. Introduction. -Chapter 1.2. 21st century SARS-CoV-2 outbreaks, epidemics. -Chapter 1.3.Worldwide surveillance systems. -Chapter 1.4. Regions of potential threat. -Chapter 1.5. Pandemic SARS-CoV-2. -Chapter 1.6. Conclusions. -Chapter 1.7. Future Perspectives. -Chapter 1.8. References. -Chapter 2_Genome organization and Pathogenesis of novel Coronavirus 2019 (SARS-CoV-2). -Chapter 2.1. Introduction. -Chapter 2.2. Structure and genome of SARS-CoV-2. -Chapter 2.3. Replication and life cycle of virus. -Chapter 2.3.1 Attachment. -Chapter 2.3.2.Entry. -Chapter 2.3.3. Receptors. -Chapter 2.3.4. Uncoating. -Chapter 2.3.5. Synthesis of viral RNA. -Chapter 2.3.6. Viral proteins . -Chapter 2.3.7. Egress. -Chapter 2.4. Conclusions. -Chapter 2.5. Future Perspectives. -Chapter 3_Host immune response against human SARS-CoV-2 infection. -Chapter 3.1. Introduction. -Chapter 3.2. Immune response. -Chapter 3.3. Humoral immune response. -Chapter 3.4.Cellular immune response. -Chapter 3.5. Conclusions. -Chapter 3.6. Future Perspectives. -Chapter 4_Emergence and Re-emergence of SARS Coronaviruses. -Chapter 4.1. Introduction. -Chapter 4.2. SARS-CoV to SARS-CoV-2: RNA recombination, antigenic shift and antigenic drift. -Chapter 4.3. Conclusions. -Chapter 4.4. Future Perspectives. -Chapter 5_Transmission cycle of SARS-CoV and SARS-CoV-2. . -Chapter 5.1. Introduction. -Chapter 5.2. Coronavirus Transmission cycle. -Chapter 5.2.1. Transmission among animals. -Chapter 5.2.2. Transmission in animals to human. -Chapter 5.2.3.Transmission among humans. -Chapter 5.2.4. Other hosts. -Chapter 5.3. Conclusions. -Chapter 5.4. Future Perspectives. -Chapter 6_Preparing for the perpetual challenges of pandemics of Coronavirus infections with special focus on SARS-CoV-2. -Chapter 6.1. Introduction. -Chapter 6.2. Strategies for pandemic preparedness for Coronavirus. -Chapter 6.2.1. Updated Surveillance system. -Chapter 6.2.2. Strategies for implementation of laboratory diagnostic services during pandemics. -Chapter 6.2.3. Management of bulk vaccines, antiviral drugs. -Chapter 6.3. Promoting facilities for treatment and hospitalisation, healthcare personnel, maintenance of hygiene and disinfection during pandemics. -Chapter 6.3.1.Global management strategies of Coronavirus infection. -Chapter 6.3.2.Economic Consequences of pandemic risk. -Chapter 6.3.3.Conclusions. -Chapter 6.3.4. Future Perspectives. -Chapter 7. Clinical manifestations and diagnosis of human SARS-CoV-2 infection. . -Chapter 7.1. Introduction. -Chapter 7.2. General Symptoms of SARS-CoV-2 infection. -Chapter 7.3. Clinical Course. -Chapter 7.4. Clinical complications. -Chapter 7.5. Diagnosis of SARS-CoV-2. -Chapter 7.6. Conclusions. -Chapter 7.7. Future Perspectives. -Chapter 8. Treatment and Drugs for SARS-CoV-2. . -Chapter 8.1. Introduction. -Chapter 8.2. Antiviral drugs for SARS-CoV-2. -Chapter 8.3. Current available drugs, Pharmacokinetics, Toxicity, Efficacy, Resistance, Drug Interactions, Recommendations for Use. . -Chapter 8.4. Complementary and alternative medicines for SARS-CoV-2. . -Chapter 8.5. Conclusions. -Chapter 8.6. Future Perspectives. -Chapter 9. Prevention and control strategies for SARS-CoV-2 infection. . -Chapter 9.1. Introduction. -Chapter 9.2. SARS-CoV-2 vaccine development. -Chapter 9.3. Types of Coronavirus vaccines. -Chapter 9.4. Efficacy and effectiveness of Coronavirus vaccines. -Chapter 9.5. Control strategies of Coronavirus infection. -Chapter 9.6. Conclusions


Saxena, Shailendra K.
Prof. (Dr.) Shailendra K. Saxena is a Vice Dean and Professor at King George's Medical University, Lucknow. His primary research interest is to understand the molecular mechanisms of host defense during human viral infections and to develop predictive, preventive and therapeutic strategies against these diseases. Prof. Saxena's work has been published in various high impact factor reputed international journals.  He has been honored by several prestigious National and International Awards, Fellowships and Scholarships in India and abroad, including Young Scientist Awards, BBSRC India Partnering Award and named as the Global Leader in Science by The Scientist magazine (USA) and International Opinion Leader/Expert that are involved in the vaccination for JE by IPIC (UK).  He has been elected Fellow of The Royal Society of Biology UK (FRSB), The Royal Society of Chemistry UK (FRSC), The Academy of Environmental Biology, India (FAEB), Indian Virological Society (FIVS), The Biotech Research Society, India (FBRS); and Fellowship of the (European) Academy of Translational Medicine Professionals, Austria (FacadTM). He has been awarded Dr. JC Bose National Award of Department of Biotechnology (DBT, Min. of Science & Technology, Govt. of India) in Biotechnology and has an active collaboration with various US universities.


WIR VERWENDEN COOKIES

Einige Cookies sind notwendig für den Betrieb der Seite, während andere uns helfen, Ihnen ein optimales Erlebnis unserer Webseite zu ermöglichen.